Files

Cortes-SerraN_Biochim_Biophys_Acta_Mol_Basis_Dis_2020_POSTPRINT.pdf (439.12 KB)

Document type

Article

Version

Accepted version

Publication date

2020-03-10

Publication license

cc-by.nc-nd (c) Elsevier, 2020
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/155058

State-of-the-art in host-derived biomarkers of Chagas disease prognosis and early evaluation of anti-Trypanosoma cruzi treatment response

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

http://dx.doi.org/10.1016/j.bbadis.2020.165758

Abstract

Chagas disease is caused by infection with the parasite Trypanosoma cruzi, which might lead to a chronic disease state and drive to irreversible damage to the heart and/or digestive tract tissues. Endemic in 21 countries in the Americas, it is the neglected disease with a highest burden in the region. Current estimates point at ~6 million people infected, of which ~30% will progress onto the symptomatic tissue disruptive stage. There is no vaccine but there are two anti-parasitic drugs available: benznidazole and nifurtimox. However, their efficacy is variable at the chronic symptomatic stage and both have frequent adverse effects. Since there are no prognosis markers, drugs should be administered to all T. cruzi-infected individuals in the indeterminate and early symptomatic stages. Nowadays, there are no tests-of-cure either, which greatly undermines patients' follow-up and the search of safer and more efficacious drugs. Therefore, the identification and validation of biomarkers of disease progression and/or treatment response on which to develop tests of prognosis and/or cure is a major research priority. Both parasite- and host-derived markers have been investigated. In the present manuscript we present an updated outlook of the latter.

Subject

Malaltia de Chagas, Marcadors bioquímics

Subject (English)

Chagas' disease, Biochemical markers

Citation

Collections

Articles publicats en revistes (ISGlobal)

Citation

CORTÉS SERRA, Núria, et al. State-of-the-art in host-derived biomarkers of Chagas disease prognosis and early evaluation of anti-Trypanosoma cruzi treatment response. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2020. Vol. 1886, num. 7. ISSN 0925-4439. [consulted: 6 of June of 2026]. Available at: https://hdl.handle.net/2445/155058

Export metadata

JSON - METS

Share record